Sort   by:  
 Page size 
UnknownA phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Not available
S-EPMC4424139 | biostudies-literature
UnknownA phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Not available
S-EPMC7957175 | biostudies-literature
UnknownPrevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Not available
S-EPMC7489343 | biostudies-literature
UnknownRenal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Not available
S-EPMC11142736 | biostudies-literature
UnknownMolecular Characterization of Appendiceal Goblet Cell Carcinoid.
Not available
S-EPMC8011958 | biostudies-literature
UnknownA phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Not available
S-EPMC6602847 | biostudies-literature
UnknownTBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Not available
S-EPMC4112043 | biostudies-literature
UnknownMolecular analysis of primary and metastatic sites in patients with renal cell carcinoma.
Not available
S-EPMC11245151 | biostudies-literature
UnknownPhase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Not available
S-EPMC8574211 | biostudies-literature
UnknownOpen-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Not available
S-EPMC6567845 | biostudies-literature
Sort   by:  
 Page size